Official educational / regulatory source · Official educational / regulatory source
Indicated for specified transplant and lymphangioleiomyomatosis uses, not aging. Immunosuppression risks and CYP3A4/P-gp interactions including grapefruit.
Explore the library
Preclinical evidencePrescription mTOR inhibitor / investigational aging research
Rapamycin
Rapamycin, also called sirolimus, is an immunosuppressant with approved disease-specific uses. Animal lifespan findings are not proof of safe or effective human anti-aging treatment.
Also indexed as: Sirolimus · Rapamune
A clear starting point
Rapamycin affects a cellular signaling system that responds to nutrients and growth signals. This also affects immunity. Slowing a pathway is not automatically beneficial throughout the body.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
FKBP12 / mTORC1 signaling
Rapamycin affects a cellular signaling system that responds to nutrients and growth signals. This also affects immunity. Slowing a pathway is not automatically beneficial throughout the body.
- Targets & processes
- FKBP12–sirolimus complex and mTORC1
- Systems & tissues
- Immune cells and growth/nutrient-sensing pathways across tissues.
What does the evidence show?
Approved transplant/lymphangioleiomyomatosis uses must be separated from aging research. The cited longevity evidence is in mice.
What this does not establish
Human lifespan extension is not established. Evidence strength shown here refers to aging, not rejection prevention.
Nature · 2009 · Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. · PMID 19587680
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Immunosuppression increases infection and malignancy risks. Mouth ulcers, lipid changes, impaired wound healing and other serious effects can occur.
Contraindications & cautions
Requires specialist assessment, including infection, pregnancy and surgical/wound-healing considerations.
Medication & supplement interactions
Strong CYP3A4/P-gp inhibitors or inducers can change exposure. Grapefruit is a relevant interaction. Do not combine medicines without professional review.
Regulatory status · United States
United States: sirolimus products have specified transplant and lymphangioleiomyomatosis indications. Not FDA-approved to treat aging or extend lifespan.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.